Compare ALAR & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALAR | MGTX |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3M | 1.1B |
| IPO Year | 2018 | 2018 |
| Metric | ALAR | MGTX |
|---|---|---|
| Price | $1.82 | $10.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $14.00 | ★ $24.57 |
| AVG Volume (30 Days) | 167.8K | ★ 824.2K |
| Earning Date | 05-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | N/A | ★ 1.30 |
| Revenue | N/A | ★ $81,391,000.00 |
| Revenue This Year | $24.51 | $141.38 |
| Revenue Next Year | $33.43 | N/A |
| P/E Ratio | $44.31 | ★ $8.50 |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $1.16 | $6.62 |
| 52 Week High | $16.56 | $15.35 |
| Indicator | ALAR | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.40 | 26.47 |
| Support Level | $1.62 | $8.84 |
| Resistance Level | $2.10 | $11.85 |
| Average True Range (ATR) | 0.21 | 0.56 |
| MACD | 0.02 | -0.28 |
| Stochastic Oscillator | 32.00 | 9.42 |
Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment: web data collection. Geographically, it derives maximum revenue from China, followed by the United States, Europe, Hong Kong, Asia-Pacific, U.K. Virgin Islands, Israel, United Arab Emirates, Middle East & Africa and other.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.